Showing results (51-60 of 292) with videos related to

Sort By:
Pageof 30
Clinical Pharmacology : Advances and Applications|March 14, 2014
Population pharmacokinetics of olprinone in healthy male volunteersTakayuki Kunisawa, Hidefumi Kasai, Makoto Suda, et al.
Clinical Pharmacology : Advances and Applications|November 30, 2016
A prospective, observational study comparing the PK/PD relationships of generic Meropenem (Mercide®) to the innovator brand in critically ill patientsMervyn Mer, Jacques Rene Snyman, Constance Elizabeth Jansen van Rensburg, et al.
Clinical Pharmacology : Advances and Applications|October 8, 2016
Glibenclamide population pharmacokinetic/pharmacodynamic modeling in South African type 2 diabetic subjectsVirendra Rambiritch, Poobalan Naidoo, Goonaseelan Pillai
Clinical Pharmacology : Advances and Applications|March 13, 2019
Modeling and simulation of the endogenous CYP3A induction marker 4β-hydroxycholesterol during enasidenib treatmentYan Li, Jamie N Connarn, Jian Chen, et al.
Clinical Pharmacology : Advances and Applications|May 7, 2015
Pharmacokinetic equivalence study of two formulations of the anticonvulsant pregabalinRaymond R Tjandrawinata, Effi Setiawati, Ratih Sofia Ika Putri, et al.
Clinical Pharmacology : Advances and Applications|August 27, 2025
Recurrent Checkpoint Inhibitor-Related Pneumonitis Refractory to Corticosteroid Treatment: A Case Report and Literature ReviewJinyu Yu, Xuanjun Liu, Xingjiao Ma, et al.
Clinical Pharmacology : Advances and Applications|March 21, 2023
Systematic Review of Safety of RTS,S with AS01 and AS02 Adjuvant Systems Using Data from Randomized Controlled Trials in Infants, Children, and AdultsWubetu Yihunie, Bekalu Kebede, Bantayehu Addis Tegegne, et al.
Clinical Pharmacology : Advances and Applications|January 29, 2014
Chronic hepatitis C: future treatmentAstrid Wendt, Xavier Adhoute, Paul Castellani, et al.
Clinical Pharmacology : Advances and Applications|May 24, 2014
Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomibR Donald Harvey
Clinical Pharmacology : Advances and Applications|February 6, 2015
Bioavailability of everolimus administered as a single 5 mg tablet versus five 1 mg tablets: a randomized, open-label, two-way crossover study of healthy volunteersKaren Thudium, Jorge Gallo, Emmanuel Bouillaud, et al.
Pageof 30